ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis - Pharmaceutical Technology

48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients. 48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients. Positive Trikafta results set a benchmark of efficacy for future CF therapies. Photo by filadendron/E+ via Getty Images. On 18 May, at the 2026 American Thoracic Society (ATS) international conference, during a poster session, a single-centre, observational cohort study was presented with results for elexacaftor/tezacaftor/ivacaftor (ETI) that focused on clinical and laboratory parameters in people with cystic fibrosis (pwCF) carrying at least one F508del allele. The therapy, also known by its brand…

Source: Pharmaceutical Technology